TheEdgeResearch
Home / Stocks / SVRA

Savara Inc. (SVRA)

NASDAQ Healthcare Biotechnology
$4.26 ▼ -18.23%
Market Cap
$939.9M
Sector
Healthcare
Industry
Biotechnology
Beta
0.25
52-Wk Range
4-7.01
CEO
Matthew Pauls
Country
US
Currency
USD

Savara Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Yardley, PA, US. The stock last traded at $4.26, down 18.23% on the session, giving a market capitalisation of $939.9M. On trailing twelve-month figures it carries a trailing P/E of -6.98, a net margin of 0.0%. Its beta of 0.25 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-6.98
Price / Sales
0.00
Price / Book
10.04
EV / EBITDA
-6.18
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.29
Current ratio
8.55
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
70
IPO date
2017-04-28
Headquarters
Yardley, PA, US
About Savara Inc.

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Comparable companies

Savara Inc. is most often compared with the following Healthcare names:

APMDTBPH
More research on SVRA
SVRA technical analysis SVRA TheEdge Score Compare against peers
Open full interactive analysis & DCF →